Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | STK33 | Q9BYT3 | 7/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | CASP7 | P55210 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5667036 | 0.91 | CDK4 (1.00) | CDK4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5669170 | 0.87 | CDK4 (0.63) | CDK4MEN1KMT2AKDM4E | |
| SCHEMBL5668012 | 0.84 | CDK4 (0.62) | CDK4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5669236 | 0.77 | CDK4 (0.75) | CDK4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5667513 | 0.75 | CDK4 (0.72) | CDK4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5668914 | 0.73 | CDK4 (0.60) | CDK4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL13866131 | 0.72 | CDK4 (0.59) | CDK4MEN1KMT2A | |
| SCHEMBL5667846 | 0.71 | CDK4 (0.55) | CDK4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5668920 | 0.69 | CDK4 (0.64) | CDK4MEN1KMT2ANPC1RAB9A | |
| SCHEMBL5669220 | 0.69 | CDK4 (0.60) | CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050176719-A1 | Novel pyrazinone derivatives | MSD K.K. (JP) | 2005-08-11 | — | — | US | claimed |
| EP-1295878-B1 | PYRAZINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | MSD K.K. (JP) | 2003-10-30 | — | — | US | claimed |
| EP-1295878-A1 | NOVEL PYRAZINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | claimed |
| US-7148224-B2 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20050176719-A1 | Novel pyrazinone derivatives | MSD K.K. (JP) | 2005-08-11 | — | — | US | disclosed |
| US-6914062-B2 | Pyrazinone derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-07-05 | — | — | US | disclosed |
| EP-1295878-B1 | PYRAZINONE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | MSD K.K. (JP) | 2003-10-30 | — | — | US | disclosed |
| EP-1295878-A1 | NOVEL PYRAZINONE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203907-A1 | An enzyme inhibitors of cyclin-dependent kinases, antitumor agents; chemical intermediate synthesis | CDK4, CDK6, CCNI | CDK4 1/4885MEN1 3495/4885KMT2A 672/4885 |
| US-20050176719-A1 | Novel pyrazinone derivatives | CDK6, CDK4, CDK16 | CDK4 2/4885MEN1 2552/4885KMT2A 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.